Literature DB >> 19002864

Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells.

François Lefloch1, Bertrand Tessier, Sébastien Chenuet, Jean-Marc Guillaume, Pierre Cans, Jean-Louis Goergen, Annie Marc.   

Abstract

The necessity to perform serum-free cultures to produce recombinant glycoproteins generally requires an adaptation procedure of the cell line to new environmental conditions, which may therefore induce quantitative and qualitative effects on the product, particularly on its glycosylation. In previous studies, desialylation of EPO produced by CHO cells was shown to be dependent on the presence of serum in the medium. In this paper, to discriminate between the effects of the adaptation procedure to serum-free medium and the effects of the absence of serum on EPO production and glycosylation, adapted and non-adapted CHO cells were grown in serum-free and serum-containing media. The main kinetics of CHO cells were determined over batch processes as well as the glycosylation patterns of produced EPO by HPCE-LIF. A reversible decrease in EPO production was observed when cells were adapted to SFX-CHO(TM) medium, as the same cells partially recovered their production capacity when cultivated in serum-containing medium or in the enriched SFM(TM) serum-free medium. More interestingly, EPO desialylation that was not observed in both serum-free media was restored if the serum-independent cells were recultured in presence of serum. In the same way, while the serum-independent cells did not release a sialidase activity in both serum-free media, a significant activity was recovered when serum was added. In fact, the cell adaptation process to serum-free conditions did not specifically affect the sialidase release and the cellular mechanism of protein desialylation, which appeared to be mainly related to the presence of serum for both adapted and non-adapted cells.

Entities:  

Year:  2006        PMID: 19002864      PMCID: PMC3449423          DOI: 10.1007/s10616-006-9039-y

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  62 in total

1.  Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design.

Authors:  G M Lee; E J Kim; N S Kim; S K Yoon; Y H Ahn; J Y Song
Journal:  J Biotechnol       Date:  1999-04-15       Impact factor: 3.307

2.  Adaptation of cell lines to serum-free culture medium.

Authors:  S Ozturk; G Kaseko; T Mahaworasilpa; H G L Coster
Journal:  Hybrid Hybridomics       Date:  2003-08

3.  Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells.

Authors:  M Takeuchi; S Takasaki; H Miyazaki; T Kato; S Hoshi; N Kochibe; A Kobata
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

4.  Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.

Authors:  M R Lifely; C Hale; S Boyce; M J Keen; J Phillips
Journal:  Glycobiology       Date:  1995-12       Impact factor: 4.313

5.  Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms.

Authors:  M Yang; M Butler
Journal:  Biotechnol Prog       Date:  2002 Jan-Feb

6.  Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation.

Authors:  M Yang; M Butler
Journal:  Biotechnol Bioeng       Date:  2000-05-20       Impact factor: 4.530

7.  Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells.

Authors:  M Gawlitzek; U Valley; R Wagner
Journal:  Biotechnol Bioeng       Date:  1998-03-05       Impact factor: 4.530

8.  Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry.

Authors:  Gerald Stübiger; Martina Marchetti; Marietta Nagano; Rudolf Grimm; Günter Gmeiner; Christian Reichel; Günter Allmaier
Journal:  J Sep Sci       Date:  2005-09       Impact factor: 3.645

9.  Na-butyrate increases the production and alpha2,6-sialylation of recombinant interferon-gamma expressed by alpha2,6- sialyltransferase engineered CHO cells.

Authors:  D Lamotte; L Buckberry; L Monaco; M Soria; N Jenkins; J M Engasser; A Marc
Journal:  Cytotechnology       Date:  1999-01       Impact factor: 2.058

10.  Enhanced erythropoietin heterogeneity in a CHO culture is caused by proteolytic degradation and can be eliminated by a high glutamine level.

Authors:  M Yang; M Butler
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

View more
  3 in total

1.  Next-generation sequencing of the Chinese hamster ovary microRNA transcriptome: Identification, annotation and profiling of microRNAs as targets for cellular engineering.

Authors:  Matthias Hackl; Tobias Jakobi; Jochen Blom; Daniel Doppmeier; Karina Brinkrolf; Rafael Szczepanowski; Stephan H Bernhart; Christian Höner Zu Siederdissen; Juan A Hernandez Bort; Matthias Wieser; Renate Kunert; Simon Jeffs; Ivo L Hofacker; Alexander Goesmann; Alfred Pühler; Nicole Borth; Johannes Grillari
Journal:  J Biotechnol       Date:  2011-03-30       Impact factor: 3.307

2.  Over-expression of a Codon Optimized Yeast Cytosolic Pyruvate Carboxylase (PYC2) in CHO Cells for an Augmented Lactate Metabolism.

Authors:  Sanjeev K Gupta; Ankit Sharma; Hiralal Kushwaha; Pratyoosh Shukla
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810

3.  Metabolic engineering of CHO cells for the development of a robust protein production platform.

Authors:  Sanjeev Kumar Gupta; Santosh K Srivastava; Ankit Sharma; Vaibhav H H Nalage; Darshita Salvi; Hiralal Kushwaha; Nikhil B Chitnis; Pratyoosh Shukla
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.